`
`1
`
`H2 blockers increase risk of
`docetaxel-induced skin toxicity
`
`[histamine
`Premedication with H2 blockers
`H2 receptor antagonists] in patients with breast cancer
`who receive docetaxel appears to be associated with an
`increased
`risk of erythrodysaesthesia and
`facial
`erythema, according to results of a study presented at
`the Annual Meeting of the American Society of Clinical
`Oncology.
`from
`data
`collected
`researchers
`Japanese
`22 institutions regarding the occurrence of grade 2 or
`higher erythrodysaesthesia and facial erythema among
`patients treated with docetaxel for breast cancer;
`patients were treated between April 2007 and March
`2008.
`Overall, the researchers identified 989 patients, most
`of whom had received docetaxel 75 mg/m2. Of these,
`852 patients had received docetaxel monotherapy and
`137 patients had received docetaxel in combination with
`capecitabine or other chemotherapeutic agents. A total
`of 204 patients received H2 blockers and these patients
`incidences
`of
`higher
`significantly
`had
`erythrodysaesthesia
`(19.6% vs 8.8%) and
`facial
`erythema (14.2% vs 3.7%), compared with those who
`did not receive H2 blockers. Patients who received
`docetaxel combination therapy had higher, but not
`significant, incidences of erythrodysaesthesia (30.2%
`vs 17.3%) and facial erythema (20.3% vs 12.0%),
`compared with docetaxel monotherapy recipients.
`
`Kawaguchi K, et al. Correlation between docetaxel-induced skin toxicity and the
`use of steroids and H2 blockers: a multi-institution survey. 45th Annual Meeting of
`the American Society of Clinical Oncology : 492s abstr. 9536, 31 May 2009.
`Available from: URL: http://www.abstract.asco.org
`801144289
`
`0114-9954/10/1257-0001/$14.95 2010 Adis Data Information BV. All rights reserved
`
`Reactions 20 Jun 2009 No. 1257
`
`AVENTIS EXHIBIT 2227
`Mylan v. Aventis IPR2016-00712